UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 1, 2005
DRAGON PHARMACEUTICAL INC.
(Exact name of registrant as specified in its charter)
Florida 0-27937 65-0142474
------- ------- ----------
(State or Other Jurisdiction of (Commission File Number) (IRS Employer
Incorporation) Identification No.)
1055 Hastings Street, Suite 1900
Vancouver, British Columbia V6E 2E9
---------------------------- -------
(Address of Principal Executive Offices) (Zip Code)
(604) 669-8817
--------------
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Section 9 - Financial Statements and Exhibits
---------------------------------
The Registrant is filing certain agreements previously entered into and
that are part of the Registrant's and Oriental Wave Holding Limited's business.
Item 9.01 Financial Statements and Exhibits
(c) Exhibits
Exhibit No. Exhibit Description
---------- -------------------
10.18* Collaboration Agreement among Transworld Pharmaceuticals
Corporation Inc., Toray Trading Corp. and Dragon
Pharmaceutical Inc., effective as of April 30, 2001.
10.19* Agent Agreement among Allwin Biotrade, Inc., Jiangsu Wuzhong
Industry Co. Ltd. and Jiangsu Wuzhong Industry Co. Ltd.
Suzhou Zhongkai Bio-Pharmaceuticals Plant, effective as of
March 12, 2004.
10.20* Development and Manufacturing Agreement between Dragon
Pharmaceutical Inc. and Polymun Scientific Immunbiologische
Forschung GmbH, effective as of October 31, 2003.
10.21* Agreement for Advance and Long Term Supply of Products by
and between Aurobindo (Datong) Bio-Pharma Co. Ltd. and
Shanxi Weiqida Pharmaceutical Co. Ltd., dated March 25,
2004.
10.22* Technology Transfer Agreement between Shanxi Weiqida
Pharmaceutical Co. Ltd and Alpha Process Trust Reg.,
effective as of August 6, 2002.
10.23* Manufacturing Agreement for Dry-freeze Levofloxacin
Injectable by and between Shanxi Weiqida Pharmaceutical Co.,
Ltd. and Shanxi Pude Pharmaceutical Co., Ltd., effective as
of April 21, 2003.
10.24* Technology Transfer Agreement between Shanxi Weiqida
Pharmaceutical Co. Ltd and Alpha Process Trust Reg.,
effective as of April 18, 2002.
* Confidential treatment requested as to certain portions, which portions are
omitted and filed separately with the Securities and Exchange Commission.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: March 1, 2005 DRAGON PHARMACEUTICAL INC.
-------------------
/s/ Maggie Deng
---------------------------------
Maggie Deng
Chief Operating Officer